Erasca, Inc. Erasca, Inc.

Erasca, Inc.

ERAS

Rankning i aktier #3403
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Aktiekurs
$14.62
Senast synkroniserad: 2026-10-20
Marknadsvärde
$5.11B
Förändring (1 dag)
7.34%
Förändring (1 år)
514.29%
Land
US
Handel Erasca, Inc. (ERAS)

Kategori

Healthcare
Historik för aktiesplit för Erasca, Inc. (ERAS)
Aktien Erasca, Inc. (symbol: ERAS) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Oct 21, 2026.
En ERAS-aktie köpt före Oct 21, 2026 motsvarar nu 0 ERAS-aktier.
Lista över aktiesplitar
År Split Multipel Kumulativ multipel
Inte tillräckligt med data för de angivna datumen.
Aktiesplitar för liknande företag eller konkurrenter
Företag Antal aktiesplitar Kumulativ multipel Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL